Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study will look into testing a new medicine called NNC0363-1063 which may be used to treat people with diabetes. The study consists of three parts: Part 1 is a single ascending dose (SAD) study that comprises two subtypes: Part 1A conducted in healthy participants and Part 1B conducted in participants with type 1 diabetes (T1D). This study part will last for about 1½ to 5½ weeks. Part 2 is a proof-of-principle (PoP) study part conducted in participants with T1D and will last for about 2½ to 6½ weeks. Part 3 is a multiple ascending dose (MAD) study part conducted in participants with T1D and will last for 3½ to 8½ weeks.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Part 1A SAD (healthy participants)
Part 1B SAD, Part 2 PoP and Part 3 MAD (participants with T1D)
Exclusion criteria
Part 1A SAD (healthy participants)
Part 1B SAD, Part 2 PoP and Part 3 MAD (participants with T1D)
Primary purpose
Allocation
Interventional model
Masking
154 participants in 7 patient groups, including a placebo group
Loading...
Central trial contact
Novo Nordisk
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal